Arbutus Biopharma ABUS 深 滬
已收盤 07-31 16:00:00 美东时间
4.34
-0.070
-1.59%
華盛通- 最 高4.4495
- 今 開4.40
- 成交量 116.79万股
- 最 低 4.27
- 昨 收 4.41
- 總市值 85.73万
- 52周最高 5.38
- 市盈率 靜 --
- 換手率 0.59%
- 52周最低 3.31
- 委 比 33.12%
- 總股本 0.00亿
- 歷史最高 31.48
- 量 比 1.09
- 振 幅 4.07%
- 歷史最低 0.821
- 每 手 1
- 風險率 0.37%
個股概要
財務分析
公司資料
相關新聞
分紅派息
- 分時圖
- 日k
- 周k
- 月k
相關新聞
更多Arbutus Biopharma Announces Filing Of Three International Lawsuits Seeking To Enforce Patents Protecting LNP Technology Against Pfizer, BioNTech And Certain Of Their Affiliates
Arbutus and its exclusive licensee, Genevant, filed three international lawsuits seeking to enforce patents protecting their innovative lipid nanoparticle ("LNP") technology against Pfizer and BioNTech Received approximately $178M from Moderna as Arbutus’ share of the noncontingent payment under th...
07-16 19:39
Arbutus Initiates International Patent Infringement Enforcement Actions Against Pfizer and BioNTech, Receives First Payment From Moderna Settlement Agreement and Announces Intent to Return Capital to Shareholders
Arbutus Biopharma and its licensee, Genevant, filed international lawsuits against Pfizer and BioNTech to enforce their lipid nanoparticle (LNP) patents. Arbutus received $178M from Moderna as part of a settlement for patent infringement. The company expects a dividend from Genevant in Q3 2026 and plans to return up to $230M to shareholders through share repurchases.
07-16 11:30
Arbutus Biopharma Q1 EPS $0.87 Beats $(0.04) Estimate, Sales $179.126M Beat $750.000K Estimate
Arbutus Biopharma (NASDAQ:ABUS) reported quarterly earnings of $0.87 per share which beat the analyst consensus estimate of $(0.04) by 2275 percent. This is a 769.23 percent increase over losses of $(0.13) per share from
05-13 19:45
Europe Clears First Flu/COVID Combo Shot From Moderna
Moderna stock rises after EU approval of flu-COVID combo vaccine mCOMBRIAX, backed by Phase 3 data showing strong immune response.
04-22 01:58
Arbutus Biopharma's Imdusiran Receives FDA's Fast Track Designation To Treat Chronic Hepatitis B
Arbutus Biopharma Corporation (Nasdaq: ABUS) ("Arbutus" or the "Company"), a clinical-stage biopharmaceutical company focused on infectious disease, today announced that the U.S. Food and Drug Administration ("FDA") has
04-15 19:33
